Dynavax Technologies Corporation (DVAX) - Net Assets

Latest as of September 2025: $534.14 Million USD

Based on the latest financial reports, Dynavax Technologies Corporation (DVAX) has net assets worth $534.14 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($946.51 Million) and total liabilities ($412.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Dynavax Technologies Corporation (DVAX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets $534.14 Million
% of Total Assets 56.43%
Annual Growth Rate N/A
5-Year Change 916.81%
10-Year Change 219.01%
Growth Volatility 211.75

Dynavax Technologies Corporation - Net Assets Trend (2000–2024)

This chart illustrates how Dynavax Technologies Corporation's net assets have evolved over time, based on quarterly financial data. Also explore Dynavax Technologies Corporation balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Dynavax Technologies Corporation (2000–2024)

The table below shows the annual net assets of Dynavax Technologies Corporation from 2000 to 2024. For live valuation and market cap data, see market cap of Dynavax Technologies Corporation.

Year Net Assets Change
2024-12-31 $596.80 Million -4.06%
2023-12-31 $622.07 Million +7.07%
2022-12-31 $581.01 Million +161.28%
2021-12-31 $222.37 Million +278.88%
2020-12-31 $58.69 Million +608.00%
2019-12-31 $8.29 Million -86.85%
2018-12-31 $63.06 Million -68.40%
2017-12-31 $199.55 Million +123.71%
2016-12-31 $89.20 Million -52.32%
2015-12-31 $187.08 Million +86.18%
2014-12-31 $100.48 Million -46.06%
2013-12-31 $186.29 Million +62.24%
2012-12-31 $114.83 Million +14.96%
2011-12-31 $99.88 Million +91.67%
2010-12-31 $52.11 Million +717.30%
2009-12-31 $6.38 Million -60.53%
2008-12-31 $16.16 Million -58.71%
2007-12-31 $39.13 Million -50.51%
2006-12-31 $79.07 Million +6.33%
2005-12-31 $74.36 Million +24.20%
2004-12-31 $59.88 Million +204.68%
2003-12-31 $-57.20 Million -1.47%
2002-12-31 $-56.37 Million -63.79%
2001-12-31 $-34.42 Million -91.22%
2000-12-31 $-18.00 Million --

Equity Component Analysis

This analysis shows how different components contribute to Dynavax Technologies Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 87771200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $125.00K 0.02%
Other Comprehensive Income $-4.72 Million -0.79%
Other Components $1.50 Billion 252.12%
Total Equity $596.80 Million 100.00%

Dynavax Technologies Corporation Competitors by Market Cap

The table below lists competitors of Dynavax Technologies Corporation ranked by their market capitalization.

Company Market Cap
Marqeta Inc
NASDAQ:MQ
 $1.76 Billion
Pavilion Real Estate Inv Trust
KLSE:5212
 $1.76 Billion
Indo Tambangraya Megah Tbk
JK:ITMG
 $1.76 Billion
Hyundai Doosan Infracore Co Ltd
KO:042670
 $1.77 Billion
Berli Jucker PCL
BK:BJC
 $1.76 Billion
Semapa
LS:SEM
 $1.76 Billion
Sk Gas
KO:018670
 $1.76 Billion
Melia Hotels
MC:MEL
 $1.76 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Dynavax Technologies Corporation's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 622,072,000 to 596,799,000, a change of -25,273,000 (-4.1%).
  • Net income of 27,309,000 contributed positively to equity growth.
  • Share repurchases of 100,000,000 reduced equity.
  • Other comprehensive income decreased equity by 2,614,000.
  • Other factors increased equity by 50,032,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $27.31 Million +4.58%
Share Repurchases $100.00 Million -16.76%
Other Comprehensive Income $-2.61 Million -0.44%
Other Changes $50.03 Million +8.38%
Total Change $- -4.06%

Book Value vs Market Value Analysis

This analysis compares Dynavax Technologies Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.46x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2000-12-31 $-152.15 $15.50 x
2001-12-31 $-229.75 $15.50 x
2002-12-31 $-331.40 $15.50 x
2003-12-31 $-398.96 $15.50 x
2004-12-31 $28.26 $15.50 x
2005-12-31 $28.70 $15.50 x
2006-12-31 $23.83 $15.50 x
2007-12-31 $7.75 $15.50 x
2008-12-31 $3.40 $15.50 x
2009-12-31 $1.58 $15.50 x
2010-12-31 $6.32 $15.50 x
2011-12-31 $7.98 $15.50 x
2012-12-31 $6.74 $15.50 x
2013-12-31 $9.49 $15.50 x
2014-12-31 $3.82 $15.50 x
2015-12-31 $5.69 $15.50 x
2016-12-31 $2.32 $15.50 x
2017-12-31 $3.79 $15.50 x
2018-12-31 $1.01 $15.50 x
2019-12-31 $0.12 $15.50 x
2020-12-31 $0.58 $15.50 x
2021-12-31 $1.67 $15.50 x
2022-12-31 $3.85 $15.50 x
2023-12-31 $4.83 $15.50 x
2024-12-31 $4.48 $15.50 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Dynavax Technologies Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 4.58%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 9.85%
  • • Asset Turnover: 0.28x
  • • Equity Multiplier: 1.65x
  • Recent ROE (4.58%) is above the historical average (-146.36%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2000 0.00% 0.00% 0.00x 0.00x $-24.92 Million
2001 0.00% -780.50% 0.16x 0.00x $-14.97 Million
2002 0.00% -1264.05% 0.05x 0.00x $-12.40 Million
2003 0.00% -2100.73% 0.03x 0.00x $-10.16 Million
2004 -26.67% -107.82% 0.20x 1.23x $-21.96 Million
2005 -27.64% -140.26% 0.18x 1.08x $-27.99 Million
2006 -67.55% -1073.90% 0.05x 1.34x $-59.76 Million
2007 -194.77% -425.54% 0.12x 3.91x $-63.05 Million
2008 -154.04% -56.15% 0.41x 6.70x $-22.18 Million
2009 -479.38% -75.81% 0.80x 7.92x $-31.20 Million
2010 -109.97% -239.28% 0.28x 1.62x $-62.52 Million
2011 -48.66% -224.84% 0.16x 1.34x $-58.59 Million
2012 -60.92% -720.08% 0.07x 1.22x $-81.43 Million
2013 -35.81% -593.01% 0.05x 1.10x $-85.35 Million
2014 -90.29% -822.35% 0.08x 1.38x $-100.77 Million
2015 -57.08% -2636.89% 0.02x 1.16x $-125.50 Million
2016 -126.06% -1018.24% 0.10x 1.23x $-121.36 Million
2017 -47.68% -29099.08% 0.00x 1.10x $-115.11 Million
2018 -251.96% -1938.27% 0.04x 3.34x $-165.21 Million
2019 -1840.77% -433.29% 0.13x 33.66x $-153.43 Million
2020 -128.19% -161.63% 0.13x 6.02x $-81.11 Million
2021 34.50% 17.46% 0.42x 4.67x $54.48 Million
2022 50.46% 40.56% 0.73x 1.70x $235.05 Million
2023 -1.03% -2.75% 0.23x 1.60x $-68.60 Million
2024 4.58% 9.85% 0.28x 1.65x $-32.37 Million

Industry Comparison

This section compares Dynavax Technologies Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $459,373,250
  • Average return on equity (ROE) among peers: -63.25%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Dynavax Technologies Corporation (DVAX) $534.14 Million 0.00% 0.77x $1.76 Billion
Aurora Cannabis Inc (ACB) $605.09 Million 0.26% 0.40x $197.35 Million
Akanda Corp (AKAN) $26.90 Million -43.34% 0.45x $1.51 Million
Akebia Ther (AKBA) $74.01 Million -330.87% 6.15x $340.21 Million
Alkermes Plc (ALKS) $1.82 Billion 13.28% 0.39x $4.62 Billion
Amylyx Pharmaceuticals Inc (AMLX) $164.76 Million -183.14% 0.18x $1.77 Billion
Amphastar P (AMPH) $337.33 Million 1.34% 0.35x $959.02 Million
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $366.97 Million 2.90% 9.74x $3.81 Billion
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $896.36 Million -18.93% 3.86x $3.57 Billion
Anika Therapeutics Inc (ANIK) $287.08 Million 1.44% 0.21x $199.00 Million
ANI Pharmaceuticals Inc (ANIP) $15.92 Million -75.48% 0.12x $1.80 Billion

About Dynavax Technologies Corporation

NASDAQ:DVAX USA Drug Manufacturers - Specialty & Generic
Market Cap
$1.76 Billion
Market Cap Rank
#6737 Global
#1980 in USA
Share Price
$15.50
Change (1 day)
+0.00%
52-Week Range
$9.36 - $15.72
All Time High
$29.70
Categories
Companies in USA Drug Manufacturers - Specialty & Generic
About

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more